

# Efficacy and safety of the new recombinant subunit vaccine for varicella zoster virus in people living with HIV

<b>Submission date</b> 13/02/2024	<b>Recruitment status</b> Recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 05/03/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 05/03/2024	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Herpes zoster (HZ) is a common result of Varicella-Zoster virus reactivation, occurring as a painful rash. Long-lasting neuropathic pain (post-herpetic neuralgia [PHN]) can persist after rash resolution in up to 20% of patients. As cell-mediated immunity is the main defence against herpes zoster, any condition associated with its impairment, including HIV infection, can lead to a higher risk of VZV reactivation. A live attenuated vaccine showed only modest effectiveness and could not be used in immunosuppressed patients.

A new vaccine (HZ/su) named Shingrix achieved outstanding results in preventing both HZ and PHN in diverse immunocompromised categories. To date data regarding HZ/su vaccine use in people living with HIV (PLWHIV) are very limited but still promising. This study will investigate the immunologic response and safety of the HZ/su vaccine in PLWHIV on effective antiretroviral treatment.

### Who can participate?

People living with HIV (PLWHIV) aged 18 years and over who are virally suppressed on antiretroviral treatment

### What does the study involve?

Participation in the study involves two additional blood samples before the first vaccine dose and 1 month after the second vaccine dose. Moreover, 1 week after both the first and the second dose patients will be given a questionnaire investigating their symptoms (via a phone call). Finally, a follow-up visit assessing possible further adverse events and/or Herpes Zoster episodes will be scheduled 6 months after the second vaccine dose.

### What are the possible benefits and risks of participating?

The main benefit will be the understanding of Herpes Zoster recombinant subunit vaccine immunogenicity in people living with HIV. Blood sampling procedures can cause bleeding, bruises, and superficial vein thrombosis (blood clots).

Where is the study run from?

Policlinico Tor Vergata of Rome, Policlinico Umberto I of Rome and San Paolo Hospital of Milan (Italy)

When is the study starting and how long is it expected to run for?

April 2023 to December 2026

Who is funding the study?

1. Società Italiana di Malattie Infettive e Tropicali (SIMIT) (Italy)
2. GlaxoSmithKline (GSK) (UK)

Who is the main contact?

1. Marco Iannetta, marco.iannetta@uniroma2.it
2. Loredana Sarmati, sarmati@med.uniroma2.it
3. Claudio Maria Mastroianni, claudio.mastroianni@uniroma1.it
4. Giulia Carla Marchetti, giulia.marchetti@unimi.it

## Contact information

### Type(s)

Public, Scientific

### Contact name

Prof Marco Iannetta

### ORCID ID

<https://orcid.org/0000-0002-6938-8627>

### Contact details

Via Montpellier, 1  
Rome  
Italy  
00133  
+39 (0)620903220  
marco.iannetta@uniroma2.it

### Type(s)

Principal investigator

### Contact name

Prof Claudio M Mastroianni

### ORCID ID

<https://orcid.org/0000-0002-1286-467X>

### Contact details

Piazzale Aldo Moro, 5  
Rome  
Italy

00185  
+39 (0)0649973073  
claudio.mastroianni@uniroma1.it

**Type(s)**

Principal investigator

**Contact name**

Prof Loredana Sarmati

**ORCID ID**

<https://orcid.org/0000-0003-1452-0333>

**Contact details**

Via Montpellier, 1  
Rome  
Italy  
00133  
+39 (0)620908192  
sarmati@med.uniroma2.it

**Type(s)**

Public, Scientific

**Contact name**

Prof Giulia C. Marchetti

**ORCID ID**

<https://orcid.org/0000-0002-4498-4828>

**Contact details**

Via Antonio di Rudinì, 8  
Milan  
Italy  
20142  
+39 (0)250323396  
giulia.marchetti@unimi.it

## **Additional identifiers**

**Clinical Trials Information System (CTIS)**

Nil known

**Protocol serial number**

AIFA\_RSO: 697

## **Study information**

**Scientific Title**

Varicella zoster recombinant HZ/su vaccine: immunogenicity and safety in people living with HIV according to LTCD4 count strata

## Acronym

HZ/su\_PLWHIV

## Study objectives

1. The HZ/su recombinant vaccine is immunogenic in people living with HIV (PLWHIV) eliciting both humoral and cell-mediated specific immunity with a high vaccine response rate (VRR) in the group of patients on-ART with high LTCD4 cell count, but poorer in those with lower LTCD4.
2. The HZ/su recombinant vaccine is safe and has an acceptable reactogenicity profile in PLWHIV in a real-life scenario, with a potential different grading according to LTCD4 count.

## Ethics approval required

Ethics approval required

## Ethics approval(s)

approved 26/05/2023, Comitato Etico indipendente Fondazione PTV Policlinico Tor Vergata (Viale Oxford 81, Rome, 00133, Italy; +39 (0)620900035; comitatoetico.lazioarea2@ptvonline.it), ref: 115.23

## Study design

Multicentric observational prospective study

## Primary study design

Observational

## Study type(s)

Safety, Efficacy

## Health condition(s) or problem(s) studied

Prevention of herpes zoster in people living with HIV

## Interventions

The present study will investigate the immunologic response and safety of the HZ/su vaccine in PLWHIV on effective antiretroviral treatment, according to the immunological situation.

Three infectious disease centers in Italy will participate in the study, prospectively enrolling a total of 500 PLWHIV (250 with current CD4+ T-lymphocyte (LTCD4) counts <350 cell/mm<sup>3</sup> and 250 with current LTCD4 ≥350 cells/mm<sup>3</sup>).

A two-dose schedule of Shingrix will be administered to adult PLWHIV (2 months apart), as recommended by national guidelines. Blood samples will be collected at baseline and 1 month after schedule completion.

The primary objective of the study is the evaluation of immunogenicity assessed in terms of vaccine response rates (VRR) as in pivotal trials, according to LTCD4 count strata. For humoral response, VRR is defined as a four-fold increase in anti-gE antibodies compared to baseline by

ELISA. In a subgroup of 100 patients (50 for each LTCD4 stratum), cell-mediated immunity will be investigated at baseline (M0) and one month (+/- 14 days) after the second HZ/su vaccine dose (M2 +1).

### **Intervention Type**

Biological/Vaccine

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

Shingrix

### **Primary outcome(s)**

HZ/su vaccine immunogenicity will be evaluated through the analysis of humoral immunity and vaccine response rate (VRR) in PLWHIV according to the current LTCD4 absolute count (cells/mm<sup>3</sup>). To this purpose, anti-glycoprotein E (gE) antibodies concentration will be assessed for the whole population at baseline (M0) and 1 month ( $\pm$  14 days) after the second HZ/su vaccine dose (M2+1). Humoral vaccine response rate (VRR) is defined as a fourfold increase over baseline (prior to vaccination) anti-gE concentration (mUI/ml).

### **Key secondary outcome(s)**

1. HZ/su reactogenicity and safety profile verified after each of the two scheduled doses in PLWHIV according to current LTCD4 absolute count (cells/mm<sup>3</sup>), using a semi-structured questionnaire investigating local and systemic symptoms, 1 week after both the first and the second dose. A follow-up visit assessing possible further adverse events and/or HZ episodes will be scheduled 6 months ( $\pm$ 1 month) after HZ/su vaccine dose 2 (M2 +6).
2. HZ/su vaccine immunogenicity evaluated through analysis of cell-mediated immunity and vaccine response rate (VRR) in PLWHIV according to current LTCD4 absolute count (cells/mm<sup>3</sup>) In a subgroup of 100 patients (50 for each LTCD4 stratum), cell-mediated immunity will be investigated at baseline (M0) and 1 month (+/- 14 days) after the second HZ/su vaccine dose (M2 +1), using an intracellular cytokine staining (ICS) assay for Interferon-gamma, IL-2, TNF-alpha, and an IFN-gamma release assay (IGRA). Cell-mediated vaccine response rate (VRR) is defined as a twofold increase over baseline (prior to vaccination) of gE-specific polypositive LTCD4 (for ICS) and a twofold increase over baseline (prior to vaccination) of gE-specific IFN-gamma production (for IGRA).
3. HZ/su vaccine immunogenicity verified through analysis of humoral and cell-mediated immunity and vaccine response rate (VRR) in PLWHIV according to the current LTCD4/CD8 ratio. In a subgroup of 100 patients (50 for each LTCD4 stratum), cell-mediated immunity will be investigated at baseline (M0) and one month (+/- 14 days) after the second HZ/su vaccine dose (M2 +1), using an intracellular cytokine staining (ICS) assay for Interferon-gamma, IL-2, TNF-alpha, and an IFN-gamma release assay (IGRA). Cell-mediated vaccine response rate (VRR) is defined as a twofold increase over baseline (prior to vaccination) of gE-specific polypositive LTCD4 (for ICS) and a twofold increase over baseline (prior to vaccination) of gE-specific IFN-gamma production (for IGRA).

### **Completion date**

31/12/2026

## **Eligibility**

**Key inclusion criteria**

1. People living with HIV (PLWHIV)  $\geq 18$  years old, on antiretroviral treatment, virally suppressed (HIVRNA  $< 50$  copies/ml in the last 6 months)
2. Able to provide informed consent
3. Available CD4 cell count in the last 6 months

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

100 years

**Sex**

All

**Key exclusion criteria**

1. Age  $< 18$  years old
2. Active herpes zoster episode at enrollment
3. Acute disease/fever at enrollment
4. Known allergy to vaccine component
5. Other than HIV immunosuppressive condition or treatment. Prednisone  $< 20$  mg/day, or equivalent, is allowed. Inhaled and topical steroids are allowed
6. Pregnancy
7. Lactation
8. Women planning to become pregnant or planning to discontinue contraceptive methods

**Date of first enrolment**

15/02/2024

**Date of final enrolment**

15/05/2026

**Locations****Countries of recruitment**

Italy

**Study participating centre**

University of Rome Tor Vergata  
Via Montpellier, 1

Rome  
Italy  
00133

**Study participating centre**  
**Sapienza, University of Rome**  
Piazzale Aldo Moro, 5  
Rome  
Italy  
00185

**Study participating centre**  
**Ospedale S. Paolo**  
Via Antonio di Rudinì, 8  
Milan  
Italy  
20142

## **Sponsor information**

**Organisation**  
University of Rome Tor Vergata

**ROR**  
<https://ror.org/02p77k626>

## **Funder(s)**

**Funder type**  
Research organisation

**Funder Name**  
Società Italiana di Malattie Infettive e Tropicali (SIMIT)

**Funder Name**  
GlaxoSmithKline

**Alternative Name(s)**

GlaxoSmithKline plc., GSK plc., GlaxoSmithKline plc, GSK

### Funding Body Type

Government organisation

### Funding Body Subtype

For-profit companies (industry)

### Location

United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be published as a supplement to the results publication

### IPD sharing plan summary

Published as a supplement to the results publication

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol file</a>			14/02/2024	No	No